A novel lineage-tracing tool reveals that hypoxic tumor cells drive tumor relapse after radiotherapy

Apostolos Menegakis,Claire Vennin,Jonathan Ient,Arjan J Groot,Lenno Krenning,Rob Klompmaker,Anoek Friskes,Mila Ilic,Ala Yaromina,Rolf Harkes,Bram van den Broek,Jan Jakob Sonke,Monique De Jong,Jolanda Piepers,Jacco van Rheenen,Marc A Vooijs,René H Medema
DOI: https://doi.org/10.1016/j.radonc.2024.110592
2024-10-18
Abstract:Purpose: Tumor hypoxia imposes a main obstacle to the efficacy of anti-cancer therapy. Understanding the cellular dynamics of individual hypoxic cells before, during and post-treatment has been hampered by the technical inability to identify and trace these cells over time. Methods and materials: Here, we present a novel lineage-tracing reporter for hypoxic cells based on the conditional expression of a HIF1a-CreERT2-UnaG biosensor that can visualize hypoxic cells in a time-dependent manner and trace the fate of hypoxic cells over time. We combine this system with multiphoton microscopy, flow cytometry, and immunofluorescence to characterize the role of hypoxic cells in tumor relapse after irradiation in H1299 tumor spheroids and in vivo xenografts. Results: We validate the reporter in monolayer cultures and we show that tagged cells colocalize in spheroids and human tumor xenografts with the hypoxic marker pimonidazole. We found that irradiation of H1299-HIFcreUnaG spheroids leads to preferential outgrowth of cells from the hypoxic core. Similarly, in xenografts tumors, although initially UnaG-positive-cells coincide with pimonidazole-positive tumor areas and they are merely quiescent, upon irradiation UnaG-positive cells enrich in regrowing tumors and are mainly proliferative. Conclusions: Collectively, our data provide clear evidence that the hypoxic cells drive tumor relapse after irradiation.
What problem does this paper attempt to address?